We provide specialty excipients and drug delivery solutions to the health industries worldwide. With a service and distribution network that spans more than 60 countries, we ensure responsiveness to the pharmaceutical industry’s needs from both regional and global perspectives.
Gattefossé Corporation serves customers in the USA, Canada, and Mexico.
Each excipient is designed to meet a unique set of formulation and functionality objectives while conforming to the highest safety, quality, and regulatory standards. Our product offer includes solubilizers, emulsifiers, bioavailability enhancers, sustained release matrix formers, and skin penetration enhancers for all routes of administration. Additionally, we develop and share formulation technologies that are designed to transform lipid excipients into viable drug delivery systems.
Formulation Development Support
The new Gattefossé Technical Center in the USA works closely with drug developers in the region, providing hands-on assistance to advance drug pipelines, to speed up drug delivery projects, and essentially shorten the development path. Free of charge services include excipient screening, formulation characterization and ultimately development of prototype formulations for oral, topical, transdermal, and other routes of administration.
Investing in the USA
With a significant surge in hiring and personnel additions to our technical teams, our group continues investments in the region – including new facilities, new equipment and most importantly human capital and talent.
The conviction that achieving an innovative edge benefits all concerned is rooted in the 135-year history of the Gattefossé enterprise. This vision is supported by our direct involvement in R&D and learning initiatives that foster knowledge sharing. Sponsoring St-Remy conferences for 50 years and AAPS scientific awards since the 1990’s are examples of such initiatives.
Safety, Regulatory, & Quality Support
Gattefossé characterizes each excipient’s physico-chemical properties and safety profiles and ensures each product has global regulatory acceptance. Every product is supported with full dossiers including safety data, regulatory standing, and updated Drug Master Files with the FDA.
We aim to simplify formulation decisions that minimize attrition rates and shorten the drug development path. For existing drugs that could benefit from improved dosing, better patient compliance, or extension of product life cycle, we emphasize innovative formulation technologies. For new drug entities that suffer from solubility and bioavailability issues, we focus on guidance for pre-formulation decisions that may be combined with innovative drug delivery approaches.
Posted Date: 7/3/2018
This record has been viewed 566 times.